Analytical Data
-
Gene name
HLA-A*02:01&B2M&Vaccinia Virus(SLSNLDFRL) Monomer
- Application
-
Alternative Names
HLA-A*0201 & B2M & Vaccinia virus (SLSNLDFRL)
-
Species
Human
-
Source
HEK293
-
Tag
C-Avi;C-His
-
Purity
Greater than 90% as determined by SDS-PAGE.
-
Uniprot
AAA59606.1 (G25-I308)&P61769
-
Expression Region
AAA59606.1 (G25-I308)&P61769 (I21-M119)&SLSNLDFRL
-
Molecular Weight
40-43 kDa and 10 kDa
-
Endotoxin
< 1.0 EU per μg protein as determined by the LAL method.
-
Form
Freeze-dried powder
-
Buffer formulation
PBS, pH7.4, containing 0.01% SKL, 1mM DTT, 5% Trehalose and Proclin300.
-
Reconstitution
Reconstitute in ddH2O to a concentration of 0.1-0.5 mg/mL. Do not vortex.
- Customization
-
Stability Test
The thermal stability is described by the loss rate. The loss rate was determined by accelerated thermal degradation test, that is, incubate the protein at 37℃ for 48h, and no obvious degradation and precipitation were observed. The loss rate isless than 8% within the expiration date under appropriate storage condition.
-
Storage & Shelf Life
Samples are stable for up to twelve months from date of receipt at -20℃ to -80℃. Store it under sterile conditions at -20℃ to -80℃. It is recommended that the protein be aliquoted for optimal storage. Avoid repeated freeze-thaw cycles.
-
Shipping
In general, recombinant proteins are supplied as lyophilized powder and shipped at ambient temperature. For bulk packages, the proteins are provided as frozen liquid and shipped with blue ice, unless otherwise requested by the customer.
Quality inspection process
Related Products
Protein Description
The study of the HLA-A*02:01/B2M/Vaccinia Virus (SLSNLDFRL) monomeric recombinant protein is rooted in the exploration of immune responses against viral infections. HLA-A*02:01 is one of the most prevalent human leukocyte antigen (HLA) class I molecules, playing a crucial role in presenting endogenous peptides, including viral epitopes, to CD8+ T cells. The vaccinia virus, a member of the Poxviridae family, serves as a model for studying viral pathogenesis and is historically significant for its role in smallpox vaccination. The SLSNLDFRL peptide, derived from the vaccinia virus, has been identified as a specific T-cell epitope capable of eliciting a strong immune response in individuals expressing the HLA-A*02:01 allele. By creating a monomeric recombinant protein that combines HLA-A*02:01, beta-2-microglobulin (B2M), and the SLSNLDFRL peptide, researchers aim to better understand the molecular interactions involved in T-cell recognition and activation. This research has implications for vaccine development and immunotherapy, particularly for designing strategies that enhance immune responses against viral infections and improve therapeutic outcomes in viral diseases. Ultimately, investigating this monomeric complex contributes to a deeper understanding of HLA-peptide presentations and the adaptive immune response, paving the way for advancements in personalized medicine and vaccine strategies.
